Dendritic NanoTechnologies Appoints Dow Chemical Licensing Manager to Board of Directors
MOUNT PLEASANT, Mich., March 28 /PRNewswire/ -- Dendritic NanoTechnologies Inc. (DNT), a technology company that is a leading developer and provider of advanced dendritic polymers, or "dendrimers," today announced it has appointed Michael Pirc, a chemical engineer and licensing manager for The Dow Chemical Company (NYSE: DOW), to the company's Board of Directors. Dendrimers are nanostructures with specific, precise and predictable physical properties that make them especially useful for targeting diseases and delivering drugs to fight them. In his capacity as Dow's business manager for the Dow Technology Licensing Business, Pirc has overseen licensing for a broad range of Dow's business ventures. At DNT, Pirc will help the company better position itself to engage companies that wish to license DNT's unique dendrimer technologies. In January, DNT announced a strategic partnership with Dow and DNT investor Starpharma, an Australia-based dendrimer developer (ASX: SPL, OTC Bulletin Board: SPHRY). This agreement means that DNT owns the world's broadest dendrimer patent portfolio (196 patents comprising 41 patent families). Pirc, who was instrumental in the agreement between Dow and DNT, and who has extensive experience with Dow's dendrimer intellectual property, is uniquely positioned to identify potential licensing arrangements for DNT's technology and help bring those arrangements to fruition. "Thanks in part to Mike's efforts while heading technology licensing at Dow, DNT was able to acquire the majority of intellectual property in the dendrimer field," said Robert Berry, chief executive officer, Dendritic NanoTechnologies. "We simply could not have found a board member who would be in a better position to help us take our comprehensive dendrimer portfolio to a wider base of licensees. In addition, with his background as a chemical engineer, his extensive research into polymers, and his experience managing dendrimer licensing with Dow, Mike comes to DNT's board with a resume that is tailor-made for the role. We're thrilled to have him on the team." "The development and agreement of mutually beneficial licensing agreements is a key element in DNT's business plan," said Mike Pirc, business manager, Dow Technology Licensing. "As a board member, I intend bring my licensing experience to bear on DNT's forthcoming business ventures, and to guide and assist Bob and his team in maximizing the potential of the company." Dendrimer technology was first developed at Dow when DNT founder Donald Tomalia was a Dow employee. DNT's initial research and licensing efforts include imaging contrast agents for new diagnostic solutions for enhancing the findings of MRIs, transfection reagents for RNA-I delivery with improved gene silencing with less toxicity, and encapsulation and release of palatinate-based anti-cancer drugs to reduce the toxicity and side effects of their use. With the assignment of the Dow patent portfolio, DNT owns the world's broadest intellectual property position in dendrimer science. About DNT Dendritic NanoTechnologies Inc. (DNT) is a technology company that is a leading developer and provider of advanced dendritic nanoscale polymers. Dendrimers are nanostructures with specific, precise and predictable physical properties that make them especially useful for pharmaceuticals, medical imaging, electronics, materials, and the mass commercial markets. DNT has a broad and comprehensive IP portfolio that comprises over 200 patents in 41 patent families -- a unique level of IP concentration among nanotechnology companies -- and has existing licensing agreements with established revenue streams for dendrimer technology. DNT's business strategy is to establish dendrimer technology, through licensing agreements, as the preferred nanotechnology enabling platform from which to build value and generate revenue for DNT and its customers. DNT's technology development is directed by Donald A. Tomalia Ph.D., the company's president and chief technical officer. Dr. Tomalia had a 25-year management and senior scientist career with The Dow Chemical Company, has numerous commercial developments including Citrucel(R) (now marketed by GlaxoSmithKline) and cationic polymerization of 2-oxazolines, and is the inventor and originator of the term "dendrimers." Incorporated in 2003, DNT is a U.S. company located in Mount Pleasant, Michigan. http://www.dnanotech.com .RELATED LINKS
SOURCE Dendritic NanoTechnologies Inc.